News
SHJBF
3.000
NaN%
--
Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results
TipRanks · 11h ago
UBS Reaffirms Their Buy Rating on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)
TipRanks · 21h ago
Junshi Biosciences’ Major Shareholder Lets Share-Sale Plan Expire Unused
TipRanks · 5d ago
Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase
TipRanks · 03/31 16:46
Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A
TipRanks · 03/20 10:40
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Receives a Buy from Citi
TipRanks · 03/18 00:29
Junshi Biosciences Chairman Continues Shareholding Increase Plan
TipRanks · 03/16 12:44
Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions
TipRanks · 03/13 14:15
Shanghai Junshi Biosciences Details Board and Committee Structure
TipRanks · 03/13 12:13
Shanghai Junshi Biosciences Sets Terms for New Strategic and ESG Board Committee
TipRanks · 03/13 12:13
Junshi Biosciences Adds ESG Focus and Revamps Pay Policies
TipRanks · 03/13 12:11
Shanghai Junshi Biosciences Lifts Revenue and Narrows Loss as Immuno-Oncology Pipeline Advances
TipRanks · 03/13 11:10
Junshi Biosciences Details Use and Return of Idle Fundraising Proceeds for Liquidity
TipRanks · 03/12 11:38
Junshi Biosciences Chairman Continues Incremental Share Purchase Plan
TipRanks · 03/10 12:11
Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China
TipRanks · 03/09 14:39
Shanghai Junshi announces NMPA acceptance of NDAs for toripalimab injection
TipRanks · 03/09 13:15
Shanghai Junshi Biosciences Sets March 2026 Board Meeting to Approve 2025 Results
TipRanks · 03/02 09:41
Junshi Biosciences Narrows 2025 Loss as Revenue Climbs Nearly 30%
TipRanks · 02/27 12:00
Junshi Biosciences Chairman Progresses RMB100 Million Shareholding Increase Plan
TipRanks · 02/10 11:48
Junshi Biosciences Forecasts Strong 2025 Revenue Growth and Narrowing Loss on TUOYI Sales
TipRanks · 01/30 11:49
More
Webull provides a variety of real-time SHJBF stock news. You can receive the latest news about Shanghai Junshi through multiple platforms. This information may help you make smarter investment decisions.
About SHJBF
Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The Company primarily operates its businesses in the domestic and American markets.